Valeant Pharmaceuticals International Inc. executives clearly wanted to look on the brighter side of life during their Feb. 28 earnings call, but a launch strategy for recently approved Siliq (brodalumab) based on clinical trial efficacy and saying that other drugs approved for psoriasis present safety issues too isn't likely to produce the sales that the Canadian company needs to reverse its recent decline.
Investors apparently didn't buy into the optimism that CEO Joseph Papa and colleagues were trying to sell on Valeant's fourth quarter and full-year earnings conference call, as the company's share price trended downward throughout the day,